Phosphorylation of Twist1 in human breast cancer cell lines and tumors

Slides:

Advertisements

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

Advertisements

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

سرطان الثدي Breast Cancer

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

IHC analyses of levels and/or phosphorylation status of selected proteins from representative sections of ventral prostate of Hi-Myc mice. IHC analyses.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers. XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers.

Phospho-Twist1–induced TGF-β2 acts as an essential mediator of signaling cross-talk between TGF-βR/Smad2 and PI3K/Akt axes. Phospho-Twist1–induced TGF-β2.

Microarray analysis of phospho-Twist1–responsive genes.

Fig. 5 Local gel scaffold for T cell memory response.

Pten deficiency induces strong stromal reaction with immune cell infiltration and promotes the development of invasive and metastatic pancreatic tumors.

BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Tyrosine phosphorylations of both DAB1 and ABL are essential for invasion of colorectal cancer cells. Tyrosine phosphorylations of both DAB1 and ABL are.

PERK signaling is constitutively activated upon EMT and promotes malignancy. PERK signaling is constitutively activated upon EMT and promotes malignancy.

mTORC1- and mTORC2-activating mutations in MTOR and RHEB

Src tethers Cas to adhesion complexes.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

SIRT1 is downregulated in human gastric cancer (GC).

Fig. 3. Enhanced EGFR signaling in Rhbdf2P159L/P159L mice.

Sustained PGC-1α loss of function triggers mesenchymal transition.

Figure Lysosome dysfunction observed in patient-derived fibroblasts with the TMEM106B p.Asp252Asn substitution Lysosome dysfunction observed in patient-derived.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.

CLIC1 promotes tumor cell spreading through effects on MLCK

Frequent alterations identified and potential actionability.

Amppos tumors are a distinct tumor subpopulation.

IL6 mRNA is not detected in metastatic prostate cancer cells.

AXL is not expressed in human prostate tumors.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

EN1 expression in breast cancer and clinical outcome.

HCCs with overexpression of biliary/progenitor marker genes.

ERK reactivation following EGFR TKI treatment.

PTB-independent ShcA pools employ distinct domains to hyperactivate mTOR and Src signaling. PTB-independent ShcA pools employ distinct domains to hyperactivate.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Changes in signal transduction pathway induced by gefitinib.

PD-L1 is expressed in breast cancer.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

Effect of CDV on human SF7796 xenografts in vivo.

ROR1 expression is inversely correlated to Wnt5A/ROR2.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Osteoactivin is overexpressed in aggressively bone metastatic 4T1 subpopulations versus weakly bone metastatic breast cancer populations. Osteoactivin.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

P53-expressing tumor cells circumvent mitosis, express markers consistent with a G1-like state, and become senescent in response to continuous chemotherapeutic.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

Heterogeneous resistance mechanisms develop in response to W+T combination treatment in the EGFRL858R/T790M genetically engineered mice. Heterogeneous.

Leukocyte populations in normal and neoplastic breast tissues.

VEGF-A inhibition impedes proliferation in Amppos tumors.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

CD36 expression in tissue adjacent and distal to the tumor.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Presentation transcript:

Phosphorylation of Twist1 in human breast cancer cell lines and tumors. Phosphorylation of Twist1 in human breast cancer cell lines and tumors. A, Twist1 mRNA was analyzed in 9 human breast cancer cell lines categorized by different HER2 level (on the basis of the published data). Met, metastatic; non-Met, nonmetastatic. B, immunoblot analysis of Twist1 phosphorylation in breast cancer cell lines with distinct metastatic potential and known genetic background. C, 4T1 cells, 4T1 tumors, and invasive human breast tumors including IDC/ILC types were stained for phospho-Twist1, Akt-pS473, and prometastatic marker TNC. Scale bars, 20 μm and 50 μm, respectively. D, pathologic statistics of 1,532 invasive human breast tumors that have phospho-Twist1. Cells with > 30% stained were considered positive. Gongda Xue et al. Cancer Discovery 2012;2:248-259 ©2012 by American Association for Cancer Research